RESUMO
Cytotoxic chemotherapy is directly linked hematologic changes during your anticancer treatment. The hematopoietic rescue agents can be used as supportive care for patients with anemia or neutropenia induced by cytotoxic chemotherapy. This study aimed to evaluate the blood count of patients undergoing chemotherapy and who made use of hematopoietic rescue workers, evaluating hematological changes induced by cytotoxic chemotherapy. This was a retrospective, descriptive and analytical study of the medical records of 36 patients undergoing chemotherapy and who used hematopoietic rescue workers at some time in their anticancer treatment in a High Complexity in Oncology Center. Of the patients included in the study population, 61% are female, and the average age of these is 57,25 years (SD ± 10,84), the most prevalent cancer among patients was the breast (48%), hematological used rescue agent is Filgrastim (53%), Erythropoietin (33%) and Erythropoietin and Filgrastim (144 The pharmacological class used in anticancer therapy in prevalence is the antimitotic taxoids and associations, representing 53% of the study population. The results of this study, as well as data from the scientific literature, demonstrate the importance of the use of hematopoietic rescue agents in chemotherapy protocols, due to the proliferative effect / therapeutic these growth factors, which reduce side effects of chemotherapy cytotoxic, giving cancer patients a better quality of life to follow your anticancer treatment, and thus increase the chance of cure.